General session I and opening ceremony

 General hepatology

Main Plenary
English
Science/Research
11 April 2019 13:30 - 15:30


Presentations

Opening Ceremony
Tom Hemming Karlsen - Norway
11 April 2019 13:30 - 14:00

GS-01 Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease: The LUBIPRONE, double-blind, randomized, placebo-controlled, phase II study
Takaomi Kessoku - Japan
11 April 2019 14:00 - 14:15

Abstract
GS-02 Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial
Philippe Wiesel - Switzerland
11 April 2019 14:15 - 14:30

Abstract
GS-03 Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts
Alessandra Mangia - Italy
11 April 2019 14:30 - 14:45

Abstract
GS-04 Addition of stent placement to angioplasty for Budd-Chiari syndrome improves recanalization patency and reduces symptom recurrence with adequate safety: A randomised controlled trial
Guohong Han - China
11 April 2019 14:45 - 15:00

Abstract
GS-05 MHC-II invariant chain adjuvanted chimpanzee adenoviral and MVA hepatitis C vaccines elicit unprecedented levels of anti-viral T-cell immune responses in humans
Ilaria Esposito - United Kingdom
11 April 2019 15:00 - 15:15

Abstract
GS-06 Positive results from REGENERATE: A phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH
Zobair Younossi - United States
11 April 2019 15:15 - 15:30

Abstract